Reinhard Ambros

Viridos, Inc. develops and commercializes genomic-driven solutions and products. The firm's offerings are designed for application in solutions such as human health, food, water production, and environment. The company was founded by J. Craig Venter, Hamilton O. Smith, David C. Kiernan and Juan Enriquez-Cabot in February 2005 and is headquartered in La Jolla, CA.

Viridos, Inc. develops and commercializes genomic-driven solutions and products. The firm's offerings are designed for application in solutions such as human health, food, water production, and environment. The company was founded by J. Craig Venter, Hamilton O. Smith, David C. Kiernan and Juan Enriquez-Cabot in February 2005 and is headquartered in La Jolla, CA.

ImmunOs Therapeutics AG is a company based in Schlieren, Switzerland that pioneers HLA-based therapeutics to create transformational medicines for cancer and inflammation. The Swiss company has identified specific HLA molecules that activate the immune system and is utilizing these molecules as the backbone of novel therapies capable of stimulating both the innate and adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs' lead program is a multi-functional fusion protein that blocks specific LILRB and KIR receptors and activates anti-tumor responses. The company is also using HLA molecules to develop novel therapies to treat inflammatory diseases. ImmunOs is supported by leading international investors, including Samsara BioCapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, Biomed Partners, Schroder Adveq, Mission BioCapital, GL Capital, Peak6, Fiscus, and Redalpine. The company was founded by Osiris Marroquin Belaunzaran and Christoph Renner, and the CEO is Sean R. Smith.

Viridos, Inc. develops and commercializes genomic-driven solutions and products. The firm's offerings are designed for application in solutions such as human health, food, water production, and environment. The company was founded by J. Craig Venter, Hamilton O. Smith, David C. Kiernan and Juan Enriquez-Cabot in February 2005 and is headquartered in La Jolla, CA.

Viridos, Inc. develops and commercializes genomic-driven solutions and products. The firm's offerings are designed for application in solutions such as human health, food, water production, and environment. The company was founded by J. Craig Venter, Hamilton O. Smith, David C. Kiernan and Juan Enriquez-Cabot in February 2005 and is headquartered in La Jolla, CA.

Artidis AG develops nano mechanical biomarkers for rapid cancer diagnostics. The private company is based in Basel, Switzerland. The Swiss company was founded by Marija Plodinec, Marko Loparic, Philipp Oertle, Tobias Appenzeller. Marija Plodinec has been the CEO since incorporation.

ImmunOs Therapeutics AG is a company based in Schlieren, Switzerland that pioneers HLA-based therapeutics to create transformational medicines for cancer and inflammation. The Swiss company has identified specific HLA molecules that activate the immune system and is utilizing these molecules as the backbone of novel therapies capable of stimulating both the innate and adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs' lead program is a multi-functional fusion protein that blocks specific LILRB and KIR receptors and activates anti-tumor responses. The company is also using HLA molecules to develop novel therapies to treat inflammatory diseases. ImmunOs is supported by leading international investors, including Samsara BioCapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, Biomed Partners, Schroder Adveq, Mission BioCapital, GL Capital, Peak6, Fiscus, and Redalpine. The company was founded by Osiris Marroquin Belaunzaran and Christoph Renner, and the CEO is Sean R. Smith.

Viridos, Inc. develops and commercializes genomic-driven solutions and products. The firm's offerings are designed for application in solutions such as human health, food, water production, and environment. The company was founded by J. Craig Venter, Hamilton O. Smith, David C. Kiernan and Juan Enriquez-Cabot in February 2005 and is headquartered in La Jolla, CA.

ImmunOs Therapeutics AG is a company based in Schlieren, Switzerland that pioneers HLA-based therapeutics to create transformational medicines for cancer and inflammation. The Swiss company has identified specific HLA molecules that activate the immune system and is utilizing these molecules as the backbone of novel therapies capable of stimulating both the innate and adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs' lead program is a multi-functional fusion protein that blocks specific LILRB and KIR receptors and activates anti-tumor responses. The company is also using HLA molecules to develop novel therapies to treat inflammatory diseases. ImmunOs is supported by leading international investors, including Samsara BioCapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, Biomed Partners, Schroder Adveq, Mission BioCapital, GL Capital, Peak6, Fiscus, and Redalpine. The company was founded by Osiris Marroquin Belaunzaran and Christoph Renner, and the CEO is Sean R. Smith.

Artidis AG develops nano mechanical biomarkers for rapid cancer diagnostics. The private company is based in Basel, Switzerland. The Swiss company was founded by Marija Plodinec, Marko Loparic, Philipp Oertle, Tobias Appenzeller. Marija Plodinec has been the CEO since incorporation.

Artidis AG develops nano mechanical biomarkers for rapid cancer diagnostics. The private company is based in Basel, Switzerland. The Swiss company was founded by Marija Plodinec, Marko Loparic, Philipp Oertle, Tobias Appenzeller. Marija Plodinec has been the CEO since incorporation.

ImmunOs Therapeutics AG is a company based in Schlieren, Switzerland that pioneers HLA-based therapeutics to create transformational medicines for cancer and inflammation. The Swiss company has identified specific HLA molecules that activate the immune system and is utilizing these molecules as the backbone of novel therapies capable of stimulating both the innate and adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs' lead program is a multi-functional fusion protein that blocks specific LILRB and KIR receptors and activates anti-tumor responses. The company is also using HLA molecules to develop novel therapies to treat inflammatory diseases. ImmunOs is supported by leading international investors, including Samsara BioCapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, Biomed Partners, Schroder Adveq, Mission BioCapital, GL Capital, Peak6, Fiscus, and Redalpine. The company was founded by Osiris Marroquin Belaunzaran and Christoph Renner, and the CEO is Sean R. Smith.

Artidis AG develops nano mechanical biomarkers for rapid cancer diagnostics. The private company is based in Basel, Switzerland. The Swiss company was founded by Marija Plodinec, Marko Loparic, Philipp Oertle, Tobias Appenzeller. Marija Plodinec has been the CEO since incorporation.

Viridos, Inc. develops and commercializes genomic-driven solutions and products. The firm's offerings are designed for application in solutions such as human health, food, water production, and environment. The company was founded by J. Craig Venter, Hamilton O. Smith, David C. Kiernan and Juan Enriquez-Cabot in February 2005 and is headquartered in La Jolla, CA.

ImmunOs Therapeutics AG is a company based in Schlieren, Switzerland that pioneers HLA-based therapeutics to create transformational medicines for cancer and inflammation. The Swiss company has identified specific HLA molecules that activate the immune system and is utilizing these molecules as the backbone of novel therapies capable of stimulating both the innate and adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs' lead program is a multi-functional fusion protein that blocks specific LILRB and KIR receptors and activates anti-tumor responses. The company is also using HLA molecules to develop novel therapies to treat inflammatory diseases. ImmunOs is supported by leading international investors, including Samsara BioCapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, Biomed Partners, Schroder Adveq, Mission BioCapital, GL Capital, Peak6, Fiscus, and Redalpine. The company was founded by Osiris Marroquin Belaunzaran and Christoph Renner, and the CEO is Sean R. Smith.

Novartis Venture Funds (NVF) is a venture capital firm with headquarters in Basel, Switzerland and an additional office in Cambridge, MA. The firm was founded in 1996. NVF is a subsidiary of Novartis AG (VX: NOVN) and was created following the 1996 merger of Ciba-Geigy and Sandoz.

Novartis Venture Funds (NVF) is a venture capital firm with headquarters in Basel, Switzerland and an additional office in Cambridge, MA. The firm was founded in 1996. NVF is a subsidiary of Novartis AG (VX: NOVN) and was created following the 1996 merger of Ciba-Geigy and Sandoz.

Viridos, Inc. develops and commercializes genomic-driven solutions and products. The firm's offerings are designed for application in solutions such as human health, food, water production, and environment. The company was founded by J. Craig Venter, Hamilton O. Smith, David C. Kiernan and Juan Enriquez-Cabot in February 2005 and is headquartered in La Jolla, CA.

Viridos, Inc. develops and commercializes genomic-driven solutions and products. The firm's offerings are designed for application in solutions such as human health, food, water production, and environment. The company was founded by J. Craig Venter, Hamilton O. Smith, David C. Kiernan and Juan Enriquez-Cabot in February 2005 and is headquartered in La Jolla, CA.

Viridos, Inc. develops and commercializes genomic-driven solutions and products. The firm's offerings are designed for application in solutions such as human health, food, water production, and environment. The company was founded by J. Craig Venter, Hamilton O. Smith, David C. Kiernan and Juan Enriquez-Cabot in February 2005 and is headquartered in La Jolla, CA.

Viridos, Inc. develops and commercializes genomic-driven solutions and products. The firm's offerings are designed for application in solutions such as human health, food, water production, and environment. The company was founded by J. Craig Venter, Hamilton O. Smith, David C. Kiernan and Juan Enriquez-Cabot in February 2005 and is headquartered in La Jolla, CA.

Cylene Pharmaceuticals, Inc. discovers, develops and commercializes small molecule drugs. It develops molecule drugs to treat life-threatening diseases, with a particular emphasis in oncology. The firm drug discovery platform, STAND has delivered a diverse portfolio of drug candidates that target the multiple pathways critical for the support, maintenance of cancer cells and that address unmet medical needs with substantial markets. The company was founded in 1997 by Thomas James Farrell and Daniel Douglas Von Hoff and is headquartered in San Diego, CA.

ImmunOs Therapeutics AG is a company based in Schlieren, Switzerland that pioneers HLA-based therapeutics to create transformational medicines for cancer and inflammation. The Swiss company has identified specific HLA molecules that activate the immune system and is utilizing these molecules as the backbone of novel therapies capable of stimulating both the innate and adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs' lead program is a multi-functional fusion protein that blocks specific LILRB and KIR receptors and activates anti-tumor responses. The company is also using HLA molecules to develop novel therapies to treat inflammatory diseases. ImmunOs is supported by leading international investors, including Samsara BioCapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, Biomed Partners, Schroder Adveq, Mission BioCapital, GL Capital, Peak6, Fiscus, and Redalpine. The company was founded by Osiris Marroquin Belaunzaran and Christoph Renner, and the CEO is Sean R. Smith.

Viridos, Inc. develops and commercializes genomic-driven solutions and products. The firm's offerings are designed for application in solutions such as human health, food, water production, and environment. The company was founded by J. Craig Venter, Hamilton O. Smith, David C. Kiernan and Juan Enriquez-Cabot in February 2005 and is headquartered in La Jolla, CA.

ImmunOs Therapeutics AG is a company based in Schlieren, Switzerland that pioneers HLA-based therapeutics to create transformational medicines for cancer and inflammation. The Swiss company has identified specific HLA molecules that activate the immune system and is utilizing these molecules as the backbone of novel therapies capable of stimulating both the innate and adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs' lead program is a multi-functional fusion protein that blocks specific LILRB and KIR receptors and activates anti-tumor responses. The company is also using HLA molecules to develop novel therapies to treat inflammatory diseases. ImmunOs is supported by leading international investors, including Samsara BioCapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, Biomed Partners, Schroder Adveq, Mission BioCapital, GL Capital, Peak6, Fiscus, and Redalpine. The company was founded by Osiris Marroquin Belaunzaran and Christoph Renner, and the CEO is Sean R. Smith.

ImmunOs Therapeutics AG is a company based in Schlieren, Switzerland that pioneers HLA-based therapeutics to create transformational medicines for cancer and inflammation. The Swiss company has identified specific HLA molecules that activate the immune system and is utilizing these molecules as the backbone of novel therapies capable of stimulating both the innate and adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs' lead program is a multi-functional fusion protein that blocks specific LILRB and KIR receptors and activates anti-tumor responses. The company is also using HLA molecules to develop novel therapies to treat inflammatory diseases. ImmunOs is supported by leading international investors, including Samsara BioCapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, Biomed Partners, Schroder Adveq, Mission BioCapital, GL Capital, Peak6, Fiscus, and Redalpine. The company was founded by Osiris Marroquin Belaunzaran and Christoph Renner, and the CEO is Sean R. Smith.

Cylene Pharmaceuticals, Inc. discovers, develops and commercializes small molecule drugs. It develops molecule drugs to treat life-threatening diseases, with a particular emphasis in oncology. The firm drug discovery platform, STAND has delivered a diverse portfolio of drug candidates that target the multiple pathways critical for the support, maintenance of cancer cells and that address unmet medical needs with substantial markets. The company was founded in 1997 by Thomas James Farrell and Daniel Douglas Von Hoff and is headquartered in San Diego, CA.

Cylene Pharmaceuticals, Inc. discovers, develops and commercializes small molecule drugs. It develops molecule drugs to treat life-threatening diseases, with a particular emphasis in oncology. The firm drug discovery platform, STAND has delivered a diverse portfolio of drug candidates that target the multiple pathways critical for the support, maintenance of cancer cells and that address unmet medical needs with substantial markets. The company was founded in 1997 by Thomas James Farrell and Daniel Douglas Von Hoff and is headquartered in San Diego, CA.

Cylene Pharmaceuticals, Inc. discovers, develops and commercializes small molecule drugs. It develops molecule drugs to treat life-threatening diseases, with a particular emphasis in oncology. The firm drug discovery platform, STAND has delivered a diverse portfolio of drug candidates that target the multiple pathways critical for the support, maintenance of cancer cells and that address unmet medical needs with substantial markets. The company was founded in 1997 by Thomas James Farrell and Daniel Douglas Von Hoff and is headquartered in San Diego, CA.

Viridos, Inc. develops and commercializes genomic-driven solutions and products. The firm's offerings are designed for application in solutions such as human health, food, water production, and environment. The company was founded by J. Craig Venter, Hamilton O. Smith, David C. Kiernan and Juan Enriquez-Cabot in February 2005 and is headquartered in La Jolla, CA.

ImmunOs Therapeutics AG is a company based in Schlieren, Switzerland that pioneers HLA-based therapeutics to create transformational medicines for cancer and inflammation. The Swiss company has identified specific HLA molecules that activate the immune system and is utilizing these molecules as the backbone of novel therapies capable of stimulating both the innate and adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs' lead program is a multi-functional fusion protein that blocks specific LILRB and KIR receptors and activates anti-tumor responses. The company is also using HLA molecules to develop novel therapies to treat inflammatory diseases. ImmunOs is supported by leading international investors, including Samsara BioCapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, Biomed Partners, Schroder Adveq, Mission BioCapital, GL Capital, Peak6, Fiscus, and Redalpine. The company was founded by Osiris Marroquin Belaunzaran and Christoph Renner, and the CEO is Sean R. Smith.

Artidis AG develops nano mechanical biomarkers for rapid cancer diagnostics. The private company is based in Basel, Switzerland. The Swiss company was founded by Marija Plodinec, Marko Loparic, Philipp Oertle, Tobias Appenzeller. Marija Plodinec has been the CEO since incorporation.

ImmunOs Therapeutics AG is a company based in Schlieren, Switzerland that pioneers HLA-based therapeutics to create transformational medicines for cancer and inflammation. The Swiss company has identified specific HLA molecules that activate the immune system and is utilizing these molecules as the backbone of novel therapies capable of stimulating both the innate and adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs' lead program is a multi-functional fusion protein that blocks specific LILRB and KIR receptors and activates anti-tumor responses. The company is also using HLA molecules to develop novel therapies to treat inflammatory diseases. ImmunOs is supported by leading international investors, including Samsara BioCapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, Biomed Partners, Schroder Adveq, Mission BioCapital, GL Capital, Peak6, Fiscus, and Redalpine. The company was founded by Osiris Marroquin Belaunzaran and Christoph Renner, and the CEO is Sean R. Smith.

Viridos, Inc. develops and commercializes genomic-driven solutions and products. The firm's offerings are designed for application in solutions such as human health, food, water production, and environment. The company was founded by J. Craig Venter, Hamilton O. Smith, David C. Kiernan and Juan Enriquez-Cabot in February 2005 and is headquartered in La Jolla, CA.

Viridos, Inc. develops and commercializes genomic-driven solutions and products. The firm's offerings are designed for application in solutions such as human health, food, water production, and environment. The company was founded by J. Craig Venter, Hamilton O. Smith, David C. Kiernan and Juan Enriquez-Cabot in February 2005 and is headquartered in La Jolla, CA.

Novartis Venture Funds (NVF) is a venture capital firm with headquarters in Basel, Switzerland and an additional office in Cambridge, MA. The firm was founded in 1996. NVF is a subsidiary of Novartis AG (VX: NOVN) and was created following the 1996 merger of Ciba-Geigy and Sandoz.

Artidis AG develops nano mechanical biomarkers for rapid cancer diagnostics. The private company is based in Basel, Switzerland. The Swiss company was founded by Marija Plodinec, Marko Loparic, Philipp Oertle, Tobias Appenzeller. Marija Plodinec has been the CEO since incorporation.

ImmunOs Therapeutics AG is a company based in Schlieren, Switzerland that pioneers HLA-based therapeutics to create transformational medicines for cancer and inflammation. The Swiss company has identified specific HLA molecules that activate the immune system and is utilizing these molecules as the backbone of novel therapies capable of stimulating both the innate and adaptive immune systems of cancer patients to eliminate tumor cells. ImmunOs' lead program is a multi-functional fusion protein that blocks specific LILRB and KIR receptors and activates anti-tumor responses. The company is also using HLA molecules to develop novel therapies to treat inflammatory diseases. ImmunOs is supported by leading international investors, including Samsara BioCapital, Lightspeed Venture Partners, Gimv, Pfizer Ventures, Biomed Partners, Schroder Adveq, Mission BioCapital, GL Capital, Peak6, Fiscus, and Redalpine. The company was founded by Osiris Marroquin Belaunzaran and Christoph Renner, and the CEO is Sean R. Smith.

Artidis AG develops nano mechanical biomarkers for rapid cancer diagnostics. The private company is based in Basel, Switzerland. The Swiss company was founded by Marija Plodinec, Marko Loparic, Philipp Oertle, Tobias Appenzeller. Marija Plodinec has been the CEO since incorporation.

Viridos, Inc. develops and commercializes genomic-driven solutions and products. The firm's offerings are designed for application in solutions such as human health, food, water production, and environment. The company was founded by J. Craig Venter, Hamilton O. Smith, David C. Kiernan and Juan Enriquez-Cabot in February 2005 and is headquartered in La Jolla, CA.